Table 1.

Myeloablative conditioning HCT for SCD

Authors	N	Median Age (years)	Conditioning	OS	Graft Rejection	DFS	cGVHD	TRM
Walters et al (2000)	50	9.4	Bu-Cy-ATG	94%	10%	84% @ 3 years	12%	6%
Bernaudin et al (2010)	144	9	Bu-Cy-ATG	95%	<2%	93% @ 3 years	10%	7%
Dedeken et al (2014)	50	8.3	Bu-Cy-ATG	94%	8%	86% @ 8 years	20%	<5%
Locatelli et al (2013)	160	–	Bu-Cy ± Thiotepa	–	<2%	90% @ 6 years	–	13%
Lucarelli et al (2014)	40	12	Bu-Cy-ATG ± Flu	91%	–	91% @ 9 years	<5%	7.5%
McPherson et al (2011)	27	8.6	Bu-Cy-ATG	96%	0%	96% @ 5 years	<5%	<5%
Vermylen et al (1998)	50	–	Bu-Cy ± TLI	93%	10%	85% @ 5 years	20%	–
Bhatia et al (2014)	18	8.9	Bu-Flu-Alemtuzumab	100%	0%	100% @ 2 years	11%	0%

OS, overall survival; DFS, disease-free survival; cGVHD, chronic graft-versus-host disease; TRM, transplant-related mortality; Bu, busulfan; Cy, cyclophosphamide; ATG, antithymocyte globulin; Flu, fludarabine; TLI, total lymphoid irradiation